Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
about
Topical pimecrolimus for eczemaEfficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials.Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life.Influence of pimecrolimus cream 1% on different morphological signs of eczema in infants with atopic dermatitis.Calcineurin inhibitors and rapamycin: cancer protection or promotion?A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Ammonium Lactate Lotion 12% and Halobetasol Propionate Ointment 0.05% in the Treatment and Maintenance of Psoriasis.Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies.Pimecrolimus cream 1% in the management of atopic dermatitis in pediatric patients: a meta-analysisGender differences in depression and anxiety among atopic dermatitis patients.A proposal: Atopic Dermatitis Organizer (ADO) guideline for childrenTherapeutic potential of macrolide immunosuppressants in dermatology.Pimecrolimus for the treatment of inflammatory skin disease.Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis.The role of topical calcineurin inhibitors in atopic dermatitis.Pimecrolimus -- an anti-inflammatory drug targeting the skin.Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis.Stress in mothers of young children with eczema.Consensus Guidelines for the Treatment of Atopic Dermatitis in Korea (Part I): General Management and Topical Treatment.Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum.Atopic dermatitis prevention.A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema.Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus.Review of pimecrolimus cream 1% in children for the treatment of mild to moderate atopic dermatitis.A systematic review of the safety of topical therapies for atopic dermatitis.Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice.Pimecrolimus versus topical corticosteroids in dermatology.Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients.An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance.Molecular pathogenesis and clinical implications of eczema herpeticum.Pathways to managing atopic dermatitis: consensus from the expertsTopical calcineurin inhibitors in dermatology. Part I: Properties, method and effectiveness of drug use.Warm, humid, and high sun exposure climates are associated with poorly controlled eczema: PEER (Pediatric Eczema Elective Registry) cohort, 2004-2012.Does eczema lead to asthma?Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials.What's new in atopic eczema?Therapeutic implications of a barrier-based pathogenesis of atopic dermatitisPimecrolimus cream in the management of patients with atopic eczema.Optimizing the treatment of atopic dermatitis in children: a review of the benefit/risk ratio of methylprednisolone aceponate.
P2860
Q24243250-D65C003F-F75E-4FEC-AC37-C22BBF585068Q31149849-5646F62E-2A68-45B7-BB23-1161BE44B16BQ34497913-30C9AD9F-2BA5-452C-8565-4A1DEA248607Q34552586-DCCFF72C-1953-4675-9B0A-94557E4E2363Q34578721-FF8400F4-08CE-4C7D-80F4-3E6C6BC444C9Q34632467-AA091033-19DD-45C2-8A32-B52B2C376AEDQ35077866-CC03AE32-52C8-4C49-962D-B5D8FA9EC82EQ35137660-C1500060-EC96-4339-B639-09D934C15A6DQ35215234-B73A1154-8A01-4E38-BDA1-BC4AAD6A19DDQ35502659-AF24B7DC-1EAA-4832-A0DC-51CEC90D1620Q35680649-DD1A01F4-3062-4E32-9C95-2C02C08C5190Q35688189-31C5B55B-1AC7-4C86-9A7D-5E4A97C5287EQ35809490-C7F76246-FBCB-4117-AEB1-848858ABD900Q35952647-340467AA-10C6-4BC2-B723-0FF8DF2003C9Q35961095-E424B7E5-0165-4B5A-BF9E-2AF52115BA5DQ36042131-3B922F9F-CE44-45C7-AF1A-DDD34C5569EBQ36155772-EAD3AA86-0646-4542-9A9D-1050377DD0F1Q36214247-40441622-00C1-4AF1-B838-AB4EB12BA83BQ36222741-7AD6C33F-34D8-491F-9AC5-9CBC127414A2Q36305883-8D16F44F-ED3F-4DED-ADC7-2D8348905D8DQ36466794-A5B72949-708B-44C6-BD80-E68DE43A9C83Q36480608-7B00C058-F0B5-40C7-B75E-867297E27A32Q36574341-F622A32E-234F-4617-AAC6-8142FEAC9D89Q36681795-65B6DF03-605D-4FB2-AD81-7160E5E36F67Q36708358-0B23180B-E59C-438B-BFEC-EAB5646CF06CQ36861654-0A38484A-6941-4A1B-B148-41231A1FDA24Q36892767-5CDE4F2E-B44A-44C1-B753-EE713DCC2381Q36895865-343DCC7E-226E-4DD7-B3E1-AA431787B625Q37049981-B582FB02-7732-40E9-9F4A-34AEE8A84C05Q37049990-B466F600-2865-42B0-B1FA-7B02A7F81529Q37213870-01F231DD-4320-4067-82C2-E4CB9CBD7A93Q37258723-ECA2DC6A-8C82-4E8D-BA75-072D15FF52C9Q37327264-F5BC0555-A073-4E1E-B1B3-581596E517E2Q37407574-77680B93-EC45-4C39-8952-7A140C72F382Q37526675-CFFBBC92-1C93-4E40-B916-6642FE230459Q37731539-05136956-03A6-4F66-BBA4-E5130979952EQ37740142-54D17C87-96BA-40FC-86C5-F396EE736724Q37822710-4B6A4223-3947-40B9-8FBF-D9E78E98CFE8Q37857666-2D4EF44A-591B-4F8A-A394-A3E5C3E1FBD4Q37865056-E4B809BE-93DD-4E56-AEB5-224DCB1B053B
P2860
Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Efficacy and safety of pimecro ...... atopic dermatitis in children.
@ast
Efficacy and safety of pimecro ...... atopic dermatitis in children.
@en
Efficacy and safety of pimecro ...... atopic dermatitis in children.
@nl
type
label
Efficacy and safety of pimecro ...... atopic dermatitis in children.
@ast
Efficacy and safety of pimecro ...... atopic dermatitis in children.
@en
Efficacy and safety of pimecro ...... atopic dermatitis in children.
@nl
prefLabel
Efficacy and safety of pimecro ...... atopic dermatitis in children.
@ast
Efficacy and safety of pimecro ...... atopic dermatitis in children.
@en
Efficacy and safety of pimecro ...... atopic dermatitis in children.
@nl
P2093
P356
P1433
P1476
Efficacy and safety of pimecro ...... atopic dermatitis in children.
@en
P2093
Ahmed Manjra
Attila Dobozy
Carle Paul
Flare Reduction in Eczema with Elidel (Children) Multicenter Investigator Study Group
Mark Goodfield
Michael Graeber
Robert Cherill
Ruggero Caputo
P356
10.1542/PEDS.110.1.E2
P407
P433
P577
2002-07-01T00:00:00Z